Physician profile
John E Ruffing
NPI 1386618817
$21,161.47
in general payments reported to CMS, 2019-2025
53 companies · $2,335 in 2025
The $2,335 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,728 · 2020: $2,995 · 2021: $4,178 · 2022: $3,307 · 2023: $2,813 · 2024: $2,805 · 2025: $2,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,953.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,770.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,272.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,922.23 | 2019-2025 | |
| Lilly USA, LLC | $1,725.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,236.52 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,111.10 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $891.40 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $773.45 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $746.67 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $677.31 | 2019-2025 | Spravato |
| Abbott Laboratories | $674.15 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $589.10 | 2019-2024 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $535.63 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $532.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $444.67 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ruffing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.